The use of FDG‐PET/CT to detect early recurrence after resection of high‐risk stage III melanoma
- 11 August 2020
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 122 (7) , 1328-1336
Abstract
Background: The role of surveillance imaging in high‐risk stage III melanoma patients after complete surgical resection remains controversial, and with the advent of adjuvant therapy, it may also be expanded. Therefore, we evaluated two fluorine‐18 fluorodeoxyglucose‐positron emission tomography/computed tomography (FDG‐PET/CT) protocols in two cohorts.Methods: Cohort 1 (n = 35) focused on surveillance in asymptomatic patients (before approval and reimbursement of adjuvant therapy) and was assigned to 5x FDG‐PET/CT's after surgery: one every 6 months for 2 years, with one final scan after 3 years. Cohort 2 (n = 42) was assigned to one screening FDG‐PET/CT, which took place in between surgery and the start of adjuvant treatment.Results: In cohort 1 (median follow‐up: 33 months), 12 patients (34.3%) developed recurrence detected by FDG‐PET/CT, of which 7 (20.0%) were detected with the first scan. Sensitivity and specificity were 92.3% and 100%, respectively. In cohort 2, recurrence was suspected on nine scans (21.4%) and four (9.5%) were true positive. The number of scans needed to find one asymptomatic recurrence were 8.8 and 10.5 in cohort 1 and 2, respectively.Conclusions: FDG‐PET/CT is a valuable imaging tool to detect recurrence in stage III melanoma, even shortly after surgery. A surveillance FDG‐PET/CT protocol after surgery or a screening PET/CT before adjuvant therapy should be considered.Keywords
This publication has 22 references indexed in Scilit:
- Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance StrategiesAnnals of Surgery, 2014
- Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanomaThe American Journal of Surgery, 2014
- The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrenceMelanoma Research, 2011
- Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single InstitutionJournal of the American College of Surgeons, 2011
- Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanomaNuclear Medicine Communications, 2010
- Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up GuidelinesJournal of Clinical Oncology, 2010
- Utility of FDG PET/CT and Brain MRI in Melanoma Patients with Increased Serum S-100B Level During Follow-upAnnals of Surgical Oncology, 2010
- Prospective Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Patients With Melanoma With Palpable Lymph Node Metastases: Diagnostic Accuracy and Impact on TreatmentJournal of Clinical Oncology, 2009
- Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive PatientsJournal of Clinical Oncology, 2006
- The Role of Fluorine-18 Deoxyglucose Positron Emission Tomography in the Management of Patients With Metastatic Melanoma: Impact on Surgical Decision MakingClinical Nuclear Medicine, 2003